Hemispherx Biopharma To Present At The 2014 Rodman & Renshaw Global Investment Conference

PHILADELPHIA - Sept. 4, 2014 - PRLog -- Hemispherx Biopharma (NYSE MKT: HEB) today announced it will be featured as a presenting company at the 16^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held September 8-10, 2014, at the New York Palace Hotel in New York City. Updates on the Company’s Alferon® N manufacturing expansion program and the Ampligen® (an experimental therapeutic) Chronic Fatigue Syndrome (CFS) program will be provided.

Dr. William A. Carter, Chairman and CEO of Hemispherx, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Emphasis will include new data on Hemispherx’s platform technologies as they relate to potential treatment and/or prevention of emerging pandemic viral threats.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event:  16^th Annual Rodman & Renshaw Global Investment Conference
Date:  Wednesday, September 10, 2013
Time:  1:15 PM Eastern Time
Location:  Kennedy I Salon, 4^th Floor; New York Palace Hotel in New York City

The presentation will be webcast live.  To access the webcast, please visit http://www.hemispherx.net  or http://www.wsw.com/webcast/rrshq24/heb.

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics, Ampligen® and Alferon® LDO.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.

Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers.

Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.  Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®), approved for sale in the U.S. and Argentina.  The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older.  The Company’s Alferon N Injection® approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.  For more information please visit www.hemispherx.net.

Disclosure Notice

The information in this press release includes certain “forward-looking” statements including without limitation statements about additional steps which the FDA may require and Hemispherx may take in continuing to seek commercial approval of the Ampligen^® NDA for the treatment of Chronic Fatigue Syndrome in the United States.  The production of new Alferon® API inventory will not commence until validation phases are complete.  While the facility is approved by FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed upon the completion of the facility's enhancements prior to commercial sale of newly produced inventory product.  If and when we obtain a reaffirmation of FDA BLA status and have begun production of new Alferon® API, we will need FDA approval as to the quality and stability of the final product to allow commercial sales to resume. The final results of these and other ongoing activities could vary materially from Hemispherx’s expectations and could adversely affect the chances for approval of the Ampligen^® NDA in the United States and other countries.  Any failure to satisfy the FDA regulatory requirements or the requirements of other countries could significantly delay, or preclude outright, approval of the Ampligen^® NDA in the United States and other countries.

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties.

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved.  These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements.  Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx’s filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.  No evidence is suggested that Alferon-N, Alferon-LDO and/or Ampligen will ever be commercially approved for any new potential treatment indications mentioned in this release including CFS, various forms of seasonal and pandemic influenza, MERS and Ebola.